King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Omar Albanyan
Dr. Omar Albanyan is a Senior Consultant Hematologist sub-specialising in chronic leukaemia and myeloproliferative neoplasms. He is a trusted Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) for patients seeking modern TKI-based therapy, JAK-inhibitor management and expert CML care in Riyadh, Saudi Arabia.
- Sub-specialty expertise in chronic myeloid leukaemia and myeloproliferative neoplasms
- Expert in all lines of TKI therapy, BCR::ABL1 mutation analysis and JAK inhibitor therapy
- Manages complex CML, polycythaemia vera, essential thrombocythaemia and myelofibrosis cases
- Experience with treatment-free remission (TFR) programmes for eligible CML patients
- Recommended for international patients seeking expert CML or MPN care in Riyadh, Saudi Arabia
Qualifications & Credentials
Medical Degrees
- MBBS — Medical University
- Residency in Internal Medicine
Fellowships & Special Training
- Fellowship in Adult Hematology
- Sub-specialty training in Chronic Leukaemia and Myeloproliferative Neoplasms
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) Registration
- Member — American Society of Hematology (ASH)
- Member — European Hematology Association (EHA)
Areas of Expertise
Major Conditions Treated
- Chronic Myeloid Leukaemia (CML) — All Phases
- Essential Thrombocythaemia (ET)
- Polycythaemia Vera (PV)
- Primary Myelofibrosis
- Chronic Lymphocytic Leukaemia (CLL)
- Chronic Eosinophilic Leukaemia
- Systemic Mastocytosis
- Acute Leukaemia Requiring HSCT
Sub-specialties
- CML & Tyrosine Kinase Inhibitor Therapy: All lines of TKI therapy including asciminib — a leading Hematologist (Chronic Leukemia) specialist in Riyadh, Saudi Arabia.
- Myeloproliferative Neoplasms: JAK inhibitors, interferon and phlebotomy management for MPNs.
- Allogeneic HSCT for CML and MPNs: Transplantation for TKI-resistant or blast phase disease.
Advanced Procedures & Treatments
- First-Line TKI Therapy (Imatinib, Dasatinib, Nilotinib)
- Second- and Third-Line TKI Therapy (Bosutinib, Ponatinib)
- STAMP Inhibitor Therapy (Asciminib)
- BCR::ABL1 Mutation Testing & Management
- Allogeneic Stem Cell Transplantation for Leukaemia
- JAK Inhibitor Therapy (Ruxolitinib) for MPNs
- Treatment-Free Remission (TFR) Monitoring in CML
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital and Research Centre (KFSHRC), Riyadh, Saudi Arabia — Consultant, Chronic Leukemia / Myeloproliferative Neoplasms Section, Department of Hematology, Stem Cell Transplantation and Cellular Therapy (Present)
Past Affiliations
- Information not publicly available.
Academic & Research Roles
- Participant — Chronic Leukaemia & MPN Multidisciplinary Tumour Board
- Teaching faculty — Haematology fellowship programme
Key Achievements
- Delivery of guideline-concordant CML therapy including second and third line TKIs
- Active contribution to institutional protocols for MPN management
- Experience with treatment-free remission programmes for eligible CML patients
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- American Society of Hematology (ASH)
- European Hematology Association (EHA)
- Saudi Society of Haematology
Research & Publications
Published Papers (Selected)
- Information not publicly available.
Ongoing Research & Clinical Interests
- Treatment-free remission (TFR) in chronic myeloid leukaemia
- BCR::ABL1 mutation management in TKI-resistant CML
- JAK inhibitor therapy in myeloproliferative neoplasms
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Haematology Consultation | SAR 500 – SAR 1,500 | $135 – $400 |
| BCR::ABL1 Molecular Monitoring | SAR 1,500 – SAR 4,000 | $400 – $1,065 |
| TKI Therapy (per month, drug-dependent) | SAR 8,000 – SAR 40,000 | $2,135 – $10,665 |
| Asciminib / Ponatinib Therapy (per month) | SAR 25,000 – SAR 60,000 | $6,660 – $16,000 |
| Allogeneic HSCT (package) | SAR 300,000 – SAR 600,000 | $80,000 – $160,000 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Dr. Omar Albanyan use in Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) treatment?
Dr. Omar Albanyan uses all lines of tyrosine kinase inhibitors (imatinib, dasatinib, nilotinib, bosutinib, ponatinib, asciminib), BCR::ABL1 mutation testing, deep molecular monitoring, JAK inhibitor therapy (ruxolitinib) for MPNs and allogeneic HSCT referral where indicated. Remote second opinions on CML and MPN cases are available via Cancer Rounds.
2. What conditions does Dr. Omar Albanyan specialize in treating?
Dr. Omar Albanyan is a Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) specialist treating chronic myeloid leukaemia (CML), polycythaemia vera, essential thrombocythaemia, primary myelofibrosis and chronic lymphocytic leukaemia. International patients seeking expert CML doctor consultations in Riyadh, Saudi Arabia are welcomed.
3. How do I book an appointment with Dr. Omar Albanyan?
Appointments with Dr. Omar Albanyan can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Omar Albanyan?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Omar Albanyan, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Dr. Omar Albanyan offer second opinions for Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) cases?
Yes. Second opinion consultations for chronic myeloid leukaemia, TKI-resistance and myeloproliferative neoplasms can be arranged via Cancer Rounds with Dr. Omar Albanyan, an expert Hematologist (Chronic Leukemia & Myeloproliferative Neoplasms) specialist in Riyadh, Saudi Arabia.
